1. Scrip
  2. >>Business

Sanofi Creates ‘Center Of Excellence’ In Pursuit Of mRNA Vaccine Rivals

‘Massive Shifts’ Coming For Sanofi Vaccine Portfolio

 
• By Alexandra Shimmings

Sanofi is beefing up its investment in mRNA vaccine technology with a €400m annual injection into a dedicated mRNA Center of Excellence as it seeks to be at the forefront of the next generation of candidates.    

mRNA - A New Vaccine Technology • Source: Alamy

French major and vaccines powerhouse Sanofi is to create a dedicated mRNA Center of Excellence as it responds to both the promise of the new technology and the corresponding threat it poses to its existing vaccines franchises, not to mention increased investment in the area by rivals.

Sanofi may have missed out on the first wave of mRNA vaccines for COVID-19 from Pfizer Inc./BioNTech SE and Moderna, Inc., but is determined not to be left behind in the next phase of the technology’s evolution

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.